text:
Swimming Pool Blog
Top 5 Pool Pump Problems
by Myles McMorrow, March 16, 2009
The pump is one of the most important parts of your pool's plumbing system. It is responsible for creating pressure in your pool, which forces the water to flow through the filter. Think of it as the heart of your swimming pool and without a filter pump your pool will rapidly become a pond of scum.
Unfortunately sometimes your pool pump will not work due to one of many issues that might occur. In this article I will cover most of the top reasons we hear at POOLCENTER.com for pool pump problems.
#1 The pump doesn't pull water.
If your pump is not moving water you first want to check the skimmer and pump baskets and make sure they are empty as not to restrict water flow. Next make sure your pool filter is clean. Once you have checked these, you may want to check the pump impeller. This is the part in the pump that is connected to the motor that moves the water. Impellers will clog from time to time, especially during the springtime. To inspect the impeller, you will need to open the pump, to see inside of the impeller housing or volute.
One of the major causes for pump suction loss is an air leak in the suction line. The suction line is where the pump gets supplied with the water from the pool. You will know this may be the issue if your pump will not catch prime. Prime is when your pump is running at full capacity. A pump is designed to suck water, but it can and will suck air if given the chance. Air has less mass than water, so a pump will suck air before it will suck water. If you think you have an air leak, see #5 below.
#2 The pump is leaking water
If you see a pump leaking water it will be on what we call the pressure side. This is after the pump lint pot ( the pot and anything before is not under positive pressure but rather negative pressure or suction and will not leak but try to draw in air see #1). The causes for a leak can be a bad impeller housing oring, bad shaft seal, or bad thread sealant or shrunken threads on the plumbing discharge pipe, or the pipe that comes out of the pump. If it is an oring or seal it is best to get what they call a Go Kit, which has every seal and oring in the pump, in one kit. I always say, if you are going to take the pump apart, you might as well replace all the seals. Pool Pump Go-Kits cost about $20, depending on the pump model and are cheaper than buying all the seals one by one.
#3 The motor will not work or turns off after time.
There can be many things that can cause this issue. You want to start by checking for power to the motor. Check your breaker and make sure your timer is set to turn on the pump. If you are getting power, the next thing to check for is sounds. Can you hear the motor hum or can you hear a click? A humming motor can mean it is the capacitor. Think of the capacitor as a battery (looks like one too) that jumps the motor to start spinning. A capacitor stores up a quick jolt of electricity to start the motor. They can be located in the back of the motor housing or in a hump on the top or side of the unit.
If your motor runs but turns itself off after a time, it may be over-heating. Pool pumps use a lot of wattage and need a constant supply. If it is in the middle of a hot day and everyone in your neighborhood has the AC on high there may be a drop of power causing the motor to overheat. Not much you can do at that point but maybe run your pump at night when it is cooler. The second leading cause for this is motor fan failure or vent blockage. On the underside of the motor are vents that can get clogged up with dirt and leaves. Make sure you do not have dirt build up and keep them open and clear. I have run across cases where was just plain old sun light causing the motor to overheat. This is common in the south west and I would recommend getting a motor cover to keep the sun at bay.
#4 The motor/pump is making a loud noise.
Everyone (and their neighbors) hates a loud swimming pool pump. If your pump is loud, the first thing to do is to listen to it. What kind of sound does it make? If it sounds like there are rocks in it, this can be from it vibrating on the pad it sits on, or it could be cavitation. A piece of rubber mat under it might help to stop the noise. If that is not the case, it may be cavitation. Cavitation happens when the pump cannot get enough water fast enough, or the pump is "starved for water". The pump impeller is spinning too fast with not enough water and starts to beat the air molecules out of the water. If you didn't just install an oversize pump, you will want to check the lines for a clog, or a closed valve. In some cases it may be a clogged filter or impeller. Clear out any obstructions and you should be fine.
Now if you pump is screaming (this is what sets off the neighbors) your motor may need new bearings. Bearings are mounted on the pool motor shaft inside the motor to help reduce the friction as the electro magnates make the motor shaft spin. This is a high wear and tear item within the motor. Although the bearings are cheap (about $15) the labor is intensive. Most motors have 2 different sizes in them and usually take special bearing pullers to remove them. I always recommend taking the motor to a shop and for about $100 you can get a motor refurbished. Or, if you are a DIY-er, we sell bearings here: Pool Motor Bearings.
#5 The motor/pump is sucking in air.
Pool pumps are supposed to be air tight. With a clear pump lid, you "should" see no air in the pump basket. This is rarely the case however, small air leaks are common. When the air leak gets too large, however, it can create problems with circulation or keeping the pump primed. The most common causes of a pump air leak include bad thread sealant where the pipe enters the pump, a leaky valve stem on one of the suction valves or a break in the plumbing. Other sources of air leaking into the system include a loose or old pump lid or pump lid o-ring or an ill fitting pump drain plug. All air leaks originate BEFORE the impeller.
A good test to locate an Air Leak, and it will sound funny - is to use shaving cream (not gel). Spread the shaving cream over the suction side joints and fittings with the pump on. The pump will try to suck the foam into the pipe because it has less resistance or mass then the water. At the air leak you will start to see the layer of foam dimple as it gets sucked into the system revealing where the leak is. At this point you will know what part needs to be repaired or replaced.
Another method of locating an air leak is to use the Drain King to pressurize the suction side. Where the water leak occurs under pressure is where the air leak occurs under suction.
So, there you have it - some of the most common reasons for pool pump aggravation. We hope to have helped you through yours!


text:
Rhyme Generator - Words that Rhyme With multipleWords which rhyme with 'multiple'; rhymes for 'multiple'
Need help? A professional poet will write or fix your poem for $5 by tomorrow. Click here...
The Rhyme Generator helps you find words easily by inserting a word into the text box and pressing Get Rhymes. The tool will then display words from within the PoemOfQuotes dictionary that fit best with the submitted text.
This rhyme machine uses several different functions to help provide the best words possible. Although not all subitted text will come up with the greatest possibilities, it is still the best generator on the web using one of the largest dictionaries available. So use it to your advantage when writing your next poem.
Working on a rap? Our rap rhyme generator is here.
Tip: Having problems? The longer the word the easier it is for the rhyme generator to find close rhymes.
Search for Rhymes anywhere by downloading RhymeGen for use in Firefox and IE.

subset: commoncrawl


text:
5 Outdoor Activities in Under 5 Minutes
Playtime is a great time to let out some positive energy! Get ready for giggles galore with these action-packed outdoor games.Download All (5)
Download All is only available to Education.com Pro members. Learn More
Click on an activity in the set below to see more info.
Play Builders and BulldozersView Full Activity
Help your child stay physically and mentally active with this group aerobic fitness game that's good for the heart and mind alike.
Play Elbow TagView Full Activity
Kids will love this more challenging version of tag where they'll have to run while "attached" to someone else.
Play Beach Burst-OutView Full Activity
Stay active over summer vacation with this fun take on the old favorite Red Rover!
Play TwistView Full Activity
Here's Twist 'N Turn: let your preschooler or pre-kindergartener be outside and active while learning about shapes, colors, directions, and word recognition.
Play Flag TagView Full Activity
Get your 4th-7th grade child outside with this fast-paced twist on the classic game of tag. This activity provides good cardiovascular exercise.
Want to download this whole set as a single PDF?Download All (5)
Download All is only available to Education.com Pro members. Learn More


text:
Open houses, Jan. 17 and 18
Homes listed around $480,000, in honor of Super Bowl XLVIII
Photo: Courtesy Heidi Ward, Windermere Real Estate
Everyone in Seattle has Seahawks fever, and the seattlepi.com real estate department is no exception.
Thus, we racked our brains for a way to tie in this week's open house gallery to Sunday's NFC Championship game. Then it hit us: If the Seahawks win, they'll be going to Super Bowl XLVIII (that's 48 for those of you who don't remember your Roman numerals).
So, here are are a few homes listed for around $480,000 that are scheduled to host open houses this weekend, but not during game time. Keep in mind that open houses are subject to cancellation on short notice.
Go Hawks!
Read more real estate news. Visit seattlepi.com's home page for more Seattle news.


text:
That depends on the cheese. If the cheese is made from pasteurized milk, it's fine. But some cheese is made with raw (unpasteurized) milk, and it's not safe to eat or drink anything made with raw milk during pregnancy.
Most cheese sold in the United States – including soft cheese – is made with pasteurized milk and is therefore considered safe to eat. But some cheese made from raw milk also shows up on store shelves and at farmer's markets, so it's best to check the label before eating any.
Soft cheeses most likely to be made from raw milk include feta, Brie, Camembert, blue-veined cheese like Roquefort and gorgonzola, and Mexican-style cheese like queso blanco, queso fresco, and panela.
Raw milk and the food made from it can carry disease-causing organisms, including a bacterium called Listeria monocytogenes. (Dairy products made from pasteurized milk, on the other hand, have a very low risk of contamination.)
Listeriosis (the infection caused by Listeria) is relatively rare. The U.S. Centers for Disease Control and Prevention (CDC) estimates that it affects 2,500 people in the United States each year. But pregnant women are particularly susceptible, and the infection can be devastating and even deadly for unborn babies.
The CDC, the U.S. Food and Drug Administration (FDA), and the U.S. Department of Agriculture (USDA) all recommend that pregnant women not eat foods made with unpasteurized milk. Raw milk soft cheeses are mentioned specifically because they've been linked to cases of listeriosis.
Why We ArchiveWhat to Expect has thousands of open discussions happening each day. We work hard to share our most timely and active conversations with you.


text:
Where do the Gingerbread Patriots stand on the fish stick issue?
John--I guess I wasn't aware that there was an "issue" so I haven't had time to form an opinion.
Megan--They would be nothing more than mush if stood on.
Jeshua--In the kitchen usually. Then I mash them between my toes and gum them with my mouth.
Ed--Cod only.
What are the pros and cons of fish in stick form?
John--Pros: When it looks like a stick it's easier to eat, I guess. Cons: "Fish sticks."
Megan--Great for meals on the run.
Ed--Pro: Cod eat it while driving. Con: Cod-n't really make a meal of them. (Those were puns.)
What do people need to know about fish sticks?
John--The facts. Like don't think that sucking on a half-thawed fish stick for nourishment is a good idea. No matter how tasty fishsicles sound, it will cause you nothing but pain.
Megan--They make their presence known ... for at least a day or two.
Jeshua--People need to know just to be careful. They will coldcock you. They'll getcha goin' one way and then bam.
Ed--They are fish in the shape of sticks, not sticks stolen from fish.
How do fish sticks relate to your lives on a macro level?
John--Just knowing that space-age food in a stick form is already here reassures us that this world is aimed at great things. This fish stick-induced optimism lubricates the machine that is Gingerbread Patriots.
Ed--I feel that fish sticks give me perspective: Nobody has ever taken me from my home, shaped my flesh rectangular-like, fried me up and made a delicious microwavable treat of me ... sometimes I take that for granted.


text:
Halloween is coming up, children love to dress up and pretend to be somebody else. We all love to pretend. Sometimes church is the place adults pretend the most. People put on a masque of perfection. "My life is fine, everything's going well." We pretend our lives, our kids' lives are just perfect because we think everyone else's lives are fine, and we are the only one with problems. We are afraid if people see us as we really are, we will be judged by others and made to feel inadequate. In reality, the masque of perfection is heavy to carry.
If you currently subscribe or have subscribed in the past to the Grant County News, then simply find your account number on your mailing label and enter it below.
Click the question mark below to see where your account ID appears on your mailing label.
|ZIP Code:


text:
Michigan State missed chances to beat a top-ranked team without anyone playing defense.
Tom Izzo, though, refused to blame his team's woes at the free throw line for helping No. 1 Indiana beat the fourth-ranked Spartans 72-68 Tuesday night.
"Games aren't lost with free throws at the end," Izzo said.
This one was won by Victor Oladipo.
Oladipo 's go-ahead putback, dunk and free throws in the final minute gave him 19 points to go along with nine rebounds, five steals and a block.
"Oladipo is just a refuse-to-lose guy," Izzo said. "Winning time, he made the plays."
Indiana (24-3, 12-2 Big Ten) broke a first-place tie in the conference — with four games left in the regular season — and moved a step closer toward earning top seeding next month in the NCAA tournament. The Hoosiers had lost 17 straight — since 1991 — on the road against the Spartans.
"Most of those guys weren't alive," Indiana coach Tom Crean said. "It didn't affect them."
Perhaps pressure got to the Spartans when they had chances to extend their lead late in the game, and to possibly push the game to overtime.
Trailing by three with 3.7 seconds left, Gary Harris was fouled on a 3-point attempt. He missed the first one — setting off sighs in the sold-out arena — and after making the second, he deliberately missed the third.
Indiana got the rebound — Oladipo got to it, of course — and he hit two free throws to seal the win.
"We were right there," Gary Harris said somberly. "And, we could've won."
Keith Appling had missed the front end of a one and one with a little more than a minute left.
"I'd say I was more upset than surprised," he said.
Michigan State (22-5, 11-3) had won five straight and 11 of 12 with its only loss during the stretch at Indiana.
Oladipo, who sprained his left ankle in his last game, had 21 points, seven rebounds, six steals and three blocks in last month's five-point win against the Spartans.
Crean insisted that the junior shooting guard "wasn't even close" to 100-percent healthy.
"There's no doubt his foot hurt," Crean said. "That mind was right, and that was the biggest thing."
Cody Zeller had 17 points — nearly doubling what he had in the previous matchup against Michigan State — while Jordan Hulls and Christian Watford scored 12 each for the Hoosiers.
Harris had 19 points, Adreian Payne scored 17 and the rest of their teammates struggled offensively.
Appling, Michigan State's leading scorer, was held to six points on 1-of-8 shooting.
"My quarterback struggled a little bit," Izzo said.
Branden Dawson scored eight and Derrick Nix had eight points and some of his contributions offensively late in the game looked like they were going to lead to a win.
Nix made a go-ahead shot — after grabbing rebounds off two of his misses — to put Michigan State ahead 64-63 lead with 3:08 left and scored again in the post on its next possession.
Harris made one of two free throws with 1:38 remaining to give the Spartans a game-high, four-point lead.
Watford responded with a three-point play on the ensuing possession to pull Indiana within a point and Oladipo did the rest.
"It was a huge win for us," Oladipo said. "We've come a long way."
The game marked the first time two top-five teams have met at the Breslin Center.
It was the third matchup of top-four teams in college basketball this season, and the second for Indiana, which beat then top-ranked Michigan It's just the fourth with a pair of Big Ten teams since 1997.
The highly anticipated and hyped game lived up to the billing with end-to-end action, scrambles for loose balls, 3-point shots, blocks in the lane and plenty of physical play.
"We didn't answer the bell," Izzo lamented.
Follow Larry Lage on Twitter: http://twitter.com/larrylage


text:
+44(0)1344 860861 •email@example.com
Ideas List
Enquiry Basket
Prices vary according to quantity and set up charges
Solid White Barrel with Pink Translucent Lid & Matching Ink. Other Colours Available. Minimum Quantity: 300.
Code: SC00104625
No stress connect with us
Contact Details
Corporate Gifts Online Ltd, Ryehurst Barn, Ryehurst Lane, Binfield, Bracknell, Berkshire,
© 2010 Corporate Gifts Online Limited. All Rights Reserved.
Company Reg. No: 04800644 VAT Reg. No: 818 0540 43


text:
The Shokado Bento is a Kaiseki Ryori for Japanese tea ceremonies in a special box (see photo of the box below) that a famous Japanese chef has created. This bento might be called the ultimate box lunch. A derivative of Kaiseki Ryori, it is a gourmet meal, self-contained in a compartmentalized box that keeps each dish separated from each other to avoid the intermingling of smells. Since our July 2011 issue, we have been building our own Zojirushi Shokado Bento one dish at a time, as we have introduced different cooking methods and various seasonal ingredients.
Since we are not in 16th century Japan, nor at a Japanese tea ceremony, we recommend relaxing a little and preparing your Shokado Bento the Zojirushi way. If you do not have a sectioned bento box, just improvise and use small plates or perhaps mini glass bowls to keep your dishes separate when serving your assembled meal. It's more important to get the feeling of Japanese cuisine in order to enjoy its beauty. Pay attention to the details--consider the different flavors as they are paired together, and the colors of the ingredients and how they look when arranged on the plate.
After we've completed our Zojirushi Shokado Bento over our next several issues, you will have experienced ingredients and dishes from all four seasons, seen a myriad of food colors and tasted an explosion of different flavors. Please look forward to it!
What is Kaiseki?
© All rights reserved.


text:
Get Started
More Info
Contact Us
Member Login
August 19th: 52,211 Roommates Available
I just had a general comment to make about the service you guys have offerred here. I'm a newcomer, and really appreciate the fact that I can register, log on, and check any new messages in such a simple manner. Nothing bothers me more than complicated paths, and you guys have made this seem like a walk in the park! keep up the fabulous service, great work! :) very satisfied user - Blair
I would like to say of the three services I utilized, yours was the most professional. You do a really solid job of providing the information to all parties, your follow up with potential matches, and providing the email outlet for easy communications. Once again thanks & I will refer you to any friends or coworkers that could utilize your service. Sincerely, Kirt
More testimonials...
Sorry, the profile that you're trying to access is currently unavailable.


text:
Pharma Sales Report: Special Force
As pressure mounts to rein in selling costs, large pharma companies have sacrificed an old standby on the altar of bottom-line profitability—face-to-face time with primary care doctors. It's been well documented how firms like Pfizer, AstraZeneca and Bristol-Myers Squibb, among others, have slashed legions of sales reps once employed to call on general practitioners, as their mass-market brands approach, and fall over, the patent cliff.
As many in Big Pharma flee the market, in many cases toward specialty drugs, their smaller cousins—specialty pharma firms and some biotechs—are going in the opposite direction, expanding investment to engage generalists, medicine's front line treating everything from hypertension and metabolic disease to pain, osteoporosis, heartburn and other conditions.
Daiichi Sankyo Inc. (DSI) is a good example. The firm had about 450 reps in 2001 and, after a four-fold increase the last decade, today fields roughly 1,700 sales people to deliver product details about its cardiovascular portfolio. On the sales force scale, that puts DSI somewhere between a Merck and a tiny player. Indeed, DSI fits the classic profile of a specialty company yet has a big presence in primary care.
"We are never going to be as large as our competition by pure numbers, ever," says Bill McLean, VP of sales at the New Jersey company. "And from the time that I've been here, we've always probably been undersized for the market that we've been into. But we've always been very successful because of one, the people we hire and two, the investment we make in training."
A formula for winning
Independent feedback from general practitioners and specialists suggests that this formula is working. DSI got very high marks in a survey in which the top sales forces were those that provided the highest-quality information, often to a smaller group of doctors. "It wasn't necessarily the biggest companies with the most feet on the street," says Jerry Maynor, US marketing and business development director, Cegedim Strategic Data, which ran the survey.
DSI's commercial operation beat out others based on the strength of information its reps deliver and their relationships with physicians and their staffs. "The companies that can bring value in and work very closely in those offices…are the ones that will win," explains McLean. "No longer will you be able to get overwhelmed and outgunned by larger companies."
That's an object lesson for a host of smaller firms looking to gain a foothold in the space. Map Pharmaceuticals has a migraine drug awaiting approval, the orally inhaled Levadex, as does NuPathe with its migraine patch Zelrix. Orexigen, which is partnered with Takeda, is knocking on FDA's door again, having reinitiated development of obesity drug Contrave in September. Among bigger biotechs, Roche/Genentech's dalcetrapib for raising "good" cholesterol and aleglitazar for diabetes are both in Phase III testing, while Amgen entered the primary care market in 2010 by launching Prolia for osteoporosis.
One of the challenges for Big Pharma has been its broad marketing and product focus. Since 2006, as many drugmakers have restructured and prepared for the loss of blockbuster business amid a productivity drought, the majors have been trying to determine the right mix of sales and marketing for their mature mass-market brands. Sales forces for the top 40 pharmas have shrunk 26%, from a peak of 101,734 in 2005 to 75,278 in 2010, according to SDI data. Industry has continued to trim commercial operations in 2011 and, considering the $50-billion patent cliff facing the industry over the next three years, don't look for the trend to come to an abrupt halt anytime soon.
Yet, even AstraZeneca's David Snow, VP of the firm's Cornerstone business unit—who has shown that the company can hold its own in primary care with less face-to-face detailing for one of its flagship brands, heartburn drug Nexium—acknowledged the power of the in-person pitch. "In changing the model, the thing I want to emphasize," he said at a marketing conference in September, "is that there's still no significant commercial tool that we've got that's more impactful than personal selling. It's still a huge impact."
Considering his remarks on the potency of direct selling, and since biopharma cannot avoid primary care, the question has become how to grab a piece of this market with a budget that's often a shadow of what it was in the go-go 1990s.
"We all know how to engage primary care when you have Lipitor, because it's easy—you target everyone, and the money's there," says Michael Luby, a former Merck marketing exec who is now CEO of BioPharma Alliance, a pharmaceutical consulting firm. "But how do you target primary care with a smaller drug where you don't have the prescribing density and the sheer volume? You have to make harder choices about where to engage and how to deploy your resources. That's the question that's perplexing the industry at all levels right now."
Smart and focused
Smaller companies like DSI think they have an answer: "It's being very smart and focused on who our customers are," explains McLean. In addition to ensuring it reaches the right physicians, DSI has evolved its sales model over the last few years to a bottom-up system that can be tweaked to react to changes in physician demographics. "If there's a market event that takes place in a local territory or district, we can quickly change the information or emphasis of the products we sell in those markets."
In addition to primary care docs, DSI reps call on cardiologists, interventional cardiologists, endocrinologists and nephrologists, and with the firm spending nearly $250 million a year to deliver details, they're expected to know their stuff. In 2008 the company completed its Learning and Conference Center, an impressive facility located near its main campus in Parsippany, NJ, designed to provide new hires with a solid foundation on the hypertension franchise: Benicar, Benicar HCT, Azor and Tribenzor. The company also markets Welchol to lower lipids as well as diabetes. (A separate specialty force promotes the antiplatelet medicine Effient through a co-promotion deal with Eli Lilly.) Pipeline drug edoxaban, a factor Xa inhibitor, could take DSI even further into the primary care arena
Experts from the American Society of Hypertension (ASH) are tapped to imbue a deep understanding, and DSI reps passing a written exam are minted as ASH-certified. Complementing new technology—iPads are standard issue for all its reps now—training adds the substance needed to carry on meaningful two-way conversations with physicians and their staff on products, disease state and healthcare as a whole.
McLean says his reps usually get a warm reception. As DSI's own customer surveys show, "we've had a lot of success in getting the message that Marketing wants us to get out to our customers.
Putting an even greater premium on skill- and relationship-building is the added difficulty for reps to gain access to primary care physicians today. The most recent reading places 12% of physicians in the "highly restricted access" group. Six months ago that was 11%. Three years ago it was only 7%, according to data from ZS Associates' AccessMonitor. "At the aggregate level, we see a small but continued erosion in physician access," reports Chris Wright, managing principal for the firm.
Tiered selling and contract reps
That hasn't scared Somaxon Pharmaceuticals from entering the primary care fray. Countering the Big Pharma in-licensing model that has largely prevailed the last 10 years, the company took its Rx insomnia drug Silenor, approved in 2010, all the way through to commercialization, albeit with mixed results.
To overcome the challenges of selling its own product without a mature commercial infrastructure, Somaxon partnered with Procter & Gamble in a tiered approach. P&G's 105-strong primary care force helped out during year one of the launch, focusing on the retail side and also covering some lower-tier physicians that wouldn't have warranted a full-time rep. P&G helped obtain distribution of Silenor down to an individual retail pharmacy store level.
Somaxon focused on high-decile doctors. Employing a strategy oft-used by companies for products later in their lifecycle, it contracted for another 140 reps from Publicis Touchpoint Solutions. In October the firm announced that most of the contracted reps would be converted to full-time Somaxon employees by the fourth quarter or early next year. Sales for Silenor, a branded version of the long-generic antidepressant doxepin, haven't exactly been on fire, though, and the firm is planning an Rx-to-OTC switch.
In the meantime, Somaxon, like DSI, has narrowly drawn its market, prioritized training and hired 25-year pharma veteran Michael Allen as SVP, sales and marketing. "The past year we've really refined our targeting," says Allen. "We understand who the primary care physicians are who are our target audience. Now it's about driving execution through the course of the product lifecycle."
Decisions on which subset of the national PCP market are detail-worthy must go beyond strictly the volume of prescriptions, Allen says. Other elements come into play: the type of practice, its location and "other healthcare market forces" unique to individual physicians. Reps should be geared to act as a resource for the entire office, from the nursing staff to the people who handle billing questions.
"Overall those healthcare professionals working in physician offices... a rep certainly has to add real value for them and a big part of that is education about a product and the therapeutic category, and prescribing information, published data, etc., but also educational tools that they can use with patients, information and tools that can help them in the increasing amount of time they spend talking to payers. When you deliver that, you're seen as an allied part of that office. That's the goal for us."
Companies like Somaxon and DSI are boldly going into primary care, as a broader commercial shakeup plays out slowly across the industry. With a lack of new products to replace aging blockbusters, pharma is seeking to keep SG&A costs in line with lower revenue to help deliver bottom-line savings for Wall Street. That means most if not all of the majors now field a leaner sales corps, and many augment it with e-detailing and other non-personal promotion.
Flex forces, which can be ramped up or down as the need arises, are set to grow, as are tiered selling approaches, at least among Big Pharma, says Craig Robertson, partner and global lead for the life sciences market at consultancy Accenture. "There's a greater focus on medical science liaisons (MSLs) and a focus on specialists going forward, with the continued need for samples in the office being addressed by almost a tiered sales force, if you will, with the lowest tier being almost the UPS delivery model, the middle tier being base promotional—product-feature-benefit discussions—and the higher tier being the MSL."
BioPharma Alliance's Luby is puzzled as to why more companies aren't experimenting aggressively with alternative channels for their in-line products. With a later-stage drug, "you're not teaching doctors anything new anymore," he explains. "Pharmaceutical companies have a hard time admitting that. So, do I need an early 20-something, $200,000/year fully loaded person to go out and educate? No. You could have a very low-paid person go and drop off samples."
That thinking may pan out for a big pharma, but it's almost anathema to a company like DSI. "Unlike other pharmaceutical companies that may have products that they can put on the shelf, we promote all of ours," says McLean. "And actually, even in a mature market like hypertension, there's still a lot of activity in that space, and we need to make sure that we have the correct share of voice to drive sales."
Nevertheless, says Robertson, "We're seeing companies continue to look at the customer interactions as, 'We need to get as many touches as we can, whether through the sales force or remote personal detailing or e-detailing, or some other inbound or outbound call center capacity.' They are looking for that ability to continue to maintain the share of voice but to do so through alternate channels."
Robertson calls it multiple channel marketing as opposed to multichannel, because "the integration of the sales force into the promotional mix of non-sales force channels really isn't there yet," he says. "There's a missed opportunity in the industry to bring those together and get some incremental value from changing that customer experience, which every physician is looking for—does this company understand who I am and are they responding to my needs?"
'Surround sound'
DSI is working on that problem, too. Making the touchpoints less disjointed is the province of its relationship marketing team. Originally, marketing campaigns were targeted toward customers, and data collected seemed siloed and focused in on only a few channels. Today, DSI says its approach is a synergistic, multi-channel "surround sound" deployment, which becomes a series of touches communicating key messages to customers. The key word there is "series," since it usually takes multiple touches for customers to recognize a message and respond.
These series of touches are tailored messages delivered by campaigns and channels (i.e., sales force, iPads coupled with interactive visual aids, e-mail, direct mail, tele-detailing and sampling, websites and speaker events using nationally known physicians). The company says differentiated and tailored customer experiences can generate growth. The data and management of the process is facilitated by its campaign management database.
For example, a patient-relationship marketing website for Welchol, called the Welchol My Progress Program, offers online registration, integrated with Welchol.com; real-time integration with co-pay card activation; real-time integration with WelcholTracker.com; and patient segmentation and a tailored communication stream.
The database uses technology and automation to segment customers, provides tailored offerings and ultimately helps increase customer value and loyalty, hence builds a better relationship, says DSI.
As the use of alternate channels grows, and social media continues to be challenging for a regulated industry, e-detailing and closed-loop marketing capabilities are changing the game. "But what we are seeing is incremental change as opposed to transformative change," observes Robertson, "and that comes from a legacy of aversion to taking big risks in some of these areas."
Granted, branded leave-behinds have largely been left behind and "customer-centric" is now the rallying cry, perhaps most famously at GlaxoSmithKline, which decided to shift the criteria for rep bonuses from sales targets to service and value provided to customers.
Robertson says companies are taking a more deliberate approach to product-lifecycle planning, including Rx-to-OTC switches. "What we're seeing is this intent to actually think through that transition much earlier in the process to not miss the opportunities to maximize the value of particular products. Companies are now seeing mature brands as being part of a very strategic approach to extending revenue."
There have also been some new approaches to call patterns, direction and alignment for field selling teams; investment in digital marketing; and creation of special business units or groups to manage mature/end-of-lifecycle brands, says TGaS Advisors, which surveyed the extent of change in commercial models (see sidebar below).
Wild cards, according to TGaS, are the extent and speed of new impact from payer pressure, health economics/outcomes research demands and comparative effectiveness hurdles. Some companies are interrogating their strategy, processes and investments in market access, asset valuation and pricing. Also unknown, says the benchmarking firm, is the extent to which the future regulatory and compliance environment will preclude today's vision of promotion and customer communication. "Some companies consider a scenario where regulatory and compliance factors will result in the dismantling of virtually all current approaches to promotion. These firms are proceeding cautiously with their investments in new promotion capabilities."
But, somewhat surprisingly, the model hasn't changed all that much. And as Big Pharma has significantly reduced its sales forces, a host of small- and mid-cap pharma and biotech firms are feeling newly emboldened to move into primary care. In some cases, TGaS found, "These companies' portfolios have been driving customer-focused strategies and tactics over time and have secured strong customer engagement by virtue of the products of value they offer. Their commercial models, particularly in the sales and reimbursement areas, have evolved over time to be fit for today and going into the future."
And two companies from the ranks of specialty pharma (the TGaS review included eight large-tier, eight mid-tier and five specialty firms) anticipate a highly stable period over the next three years with regard to their commercial model.
What does the future hold for DSI? "I don't see any significant [commercial] changes over the next three years, since we just changed our model," says McLean. He recognizes the changing landscape with regard to technology as well as the growing influence of payers but anticipates a stable period. That doesn't mean standing still. "We've been at this for a long time, grown a lot and never lost focus on what it takes to be successful."
Real change comes slowly to pharma sales ops
Despite all the ink spilled about the broken state of the pharma commercial model and how leaders are scrambling to innovate, change is not coming as fast, as profoundly or as dramatically as some would think. A systemic review of changes undertaken or planned by industry in the US shows that only three of 21 companies have recently reorganized their strategy, structure or process substantially, according to a report from TGaS Advisors.
About half anticipate a change in their commercial model approaches or ways of working, and only a third foresee a completely reworked organization by 2012.
"Overall, for most companies, the imperative for radical transformation continues to be on the distant horizon," wrote TGaS's Anna McClafferty, a VP and author of the report.
Most change will occur in the marketing discipline, she notes. Of course, many firms have been laying off large swaths of sales reps, but a downsizing effort, while significant in terms of its impact on people, is not in and of itself a true change, the report says. Most of these organizational structures remain relatively stable, near term.
That said, virtually all companies fully expect to develop new approaches to leveraging non-personal selling, multiple alternative communications channels and sophisticated customer relationship management (CRM) capabilities within three years, TGaS found.
In a few cases, industry has done more than just downsize. In 2005, with its Pravachol lipid med teetering at the edge of expiry, Bristol-Myers Squibb halved sales calls for the drug and told reps to call only on existing prescribers. Prescription rates for the drug held steady. Pfizer, laying off thousands of reps ahead of megablockbuster Lipitor's patent sunset—scheduled for this month—has been exploring alternatives for its established products, including white-space targeting, or using a halo of non-personal touchpoints.
One of the most visible examples of companies experimenting with changing their commercial model has been AstraZeneca's move, in late 2008, to start lowering the sales headcount for its $4.9 billion/year heartburn drug Nexium and replace it with a 300-person call center. By the end of 2009, virtually all detailing was eliminated, yet the company has been able to hold its sales line for Nexium through 2010.
The company also shifted a portion of its portfolio more toward bottom-line profitability. AZ created a late-stage, more mature product category called Cornerstone, where it could try alternatives to the large sales forces. The catalyst for the new unit was bringing Nexium, whose patent is due to expire in 2014, into the Cornerstone fold.
"While we continue to reduce the overall spending of Nexium, it didn't go away," said AstraZeneca's David Snow, VP of Cornerstone, in September at the DTC Performance-Based Marketing Summit. "We just changed the way we did it. A big part of it later on was how we resourced it from the large sales forces. We kept a lot of activity going on the marketing side but found a different way to represent the product in front of HCPs."
Why aren't there more examples of innovation involving flagship brands? Craig Robertson, partner and global lead for the life sciences market at consultancy Accenture, chalks it up to risk aversion. "The pain of not changing is not great enough to facilitate change yet," he says. More change is coming though, he predicts, as profits and operating income start to get squeezed and shareholders begin to demand it. Over the next 12-24 months, "I would speculate you will see significant, dramatic action… changing the customer-engagement model."